Victory Capital Management Inc. Increases Position in Boston Scientific Co. (NYSE:BSX)

Victory Capital Management Inc. increased its holdings in Boston Scientific Co. (NYSE:BSX) by 4.6% during the 4th quarter, HoldingsChannel reports. The fund owned 541,854 shares of the medical equipment provider’s stock after acquiring an additional 23,807 shares during the quarter. Victory Capital Management Inc.’s holdings in Boston Scientific were worth $31,325,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Hartford Funds Management Co LLC increased its holdings in Boston Scientific by 9.0% during the 4th quarter. Hartford Funds Management Co LLC now owns 5,141 shares of the medical equipment provider’s stock worth $297,000 after purchasing an additional 426 shares during the last quarter. Savant Capital LLC increased its stake in shares of Boston Scientific by 2.8% in the fourth quarter. Savant Capital LLC now owns 12,955 shares of the medical equipment provider’s stock worth $749,000 after buying an additional 350 shares during the last quarter. Brighton Jones LLC raised its holdings in Boston Scientific by 8.9% in the fourth quarter. Brighton Jones LLC now owns 4,353 shares of the medical equipment provider’s stock valued at $252,000 after acquiring an additional 354 shares in the last quarter. Certuity LLC bought a new position in Boston Scientific during the 4th quarter valued at $207,000. Finally, Kestra Private Wealth Services LLC boosted its stake in Boston Scientific by 5.6% during the 4th quarter. Kestra Private Wealth Services LLC now owns 18,570 shares of the medical equipment provider’s stock valued at $1,074,000 after acquiring an additional 992 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on BSX shares. Citigroup upped their target price on shares of Boston Scientific from $79.00 to $85.00 and gave the company a “buy” rating in a research note on Thursday, April 25th. StockNews.com cut Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, March 16th. Royal Bank of Canada lifted their target price on Boston Scientific from $78.00 to $82.00 and gave the stock an “outperform” rating in a research report on Thursday, April 25th. UBS Group boosted their price target on Boston Scientific from $74.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, April 25th. Finally, Raymond James raised their price objective on Boston Scientific from $73.00 to $85.00 and gave the stock a “strong-buy” rating in a research note on Thursday, April 25th. Three equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $75.09.

Insider Activity at Boston Scientific

In related news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $66.89, for a total value of $467,092.87. Following the completion of the transaction, the executive vice president now owns 56,508 shares in the company, valued at approximately $3,779,820.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Boston Scientific news, EVP John Bradley Sorenson sold 17,587 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $71.50, for a total value of $1,257,470.50. Following the completion of the sale, the executive vice president now directly owns 50,638 shares in the company, valued at $3,620,617. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $66.89, for a total value of $467,092.87. Following the transaction, the executive vice president now owns 56,508 shares in the company, valued at $3,779,820.12. The disclosure for this sale can be found here. Insiders have sold a total of 78,384 shares of company stock worth $5,395,560 over the last ninety days. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Stock Up 1.2 %

Shares of Boston Scientific stock opened at $73.43 on Wednesday. Boston Scientific Co. has a 1-year low of $48.35 and a 1-year high of $74.39. The company has a market capitalization of $107.73 billion, a P/E ratio of 61.71, a PEG ratio of 2.51 and a beta of 0.77. The business’s fifty day moving average price is $68.68 and its two-hundred day moving average price is $61.74. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.66 and a quick ratio of 1.14.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.